As part of the CVMM International Speaker Fellowship, internationally recognised hypertension researcher Professor Graeme Eisenhofer recently visited 鶹madou.
Prof Eisenhofer's visit focused on primary aldosteronism (PA) – a treatable hormone condition that causes high blood pressure, affecting millions of people worldwide but often going undetected. His expertise in steroid profiling and machine learning provided a valuable foundation for discussions on developing more accurate, less invasive, and cost-effective diagnostic tools.
It has been rewarding to appreciate how our international collaborative efforts have provided a root system to advance nationwide improvements in health care in Australia for patients with endocrine hypertension, Prof Eisenhofer
Building on Existing Partnerships
The visit strengthened existing collaborations with Prince of Wales Hospital (POWH) and 鶹madou that began in 2017 through NSW Health Pathology and Professor Andrea Horvath. These efforts led to the PROSALDO trial (a diagnostic study completed in 2024, which tests a new blood assay for its usefulness in the diagnosis of primary aldosteronism.) and a Complex Hypertension Clinic at POWH, led by A/Prof. Sradha Kotwal. This clinic uniquely combines advanced blood testing with artificial intelligence for personalized treatment of complex hypertension.
Creating Better Tools for Doctors and Patients
During his visit, Professor Eisenhofer collaborated with 鶹madou researchers to plan the next phase of research.
We’re now preparing for a new series of randomised controlled trials to evaluate the efficiency, safety and cost-effectiveness of clinical decision support systems.
This fellowship brings together multidisciplinary experts to align 鶹madou's strengths in personalized medicine and AI with national research priorities.
“Professor Eisenhofer's visit was instrumental in refining our trial design and patient selection criteria. It’s laid the foundation for a strong, fundable national study,” said A/Professor Kotwal.
The visit created connections across 鶹madou attracting a diverse audience from the Faculty of Medicine and Health (FMH), including laboratory scientists, clinicians, and data scientists.
The visit concluded with plans for quarterly multi-center meetings across NSW and a clear roadmap for future trials aimed at developing better, less invasive, and more affordable diagnostic methods for hypertension causes.